Disc Medicine, Inc. (IRON)
Disc Medicine develops experimental drugs for serious blood disorders, based in Watertown, Massachusetts. It last closed at $76.57 on Nov 17, down 0.03% on the day. The average 12-month price target from 8 analysts is $122.50 (+60.0% from the last close), with a high of $170.00 and a low of $92.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (8 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 5 whale options trades in IRON, 40% of them bullish and 60% bearish. In the past 30 days there were 3 dark pool prints totaling $8.6M, the largest $6.1M.
Key Stats
Last 12 monthsNot reported for this period.
From IRON's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 8 analysts who set a price target on IRON in the past 90 days. The average target is $122.50, with a high of $170.00 and a low of $92.00, compared with the last close of $76.57.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 9 | Guggenheim | Initiated | Buy | $132 |
| Nov 6 | HC Wainwright & Co. | Target raised | Buy | $120 → $127 |
| Oct 20 | Morgan Stanley | Target raised | Buy | $85 → $92 |
| Oct 20 | Truist Securities | Maintained | Buy | $115 |
| Oct 20 | Wells Fargo | Target raised | Buy | $86 → $124 |
Technical Analysis
The stock sits between its 20 and 50 day averages. It is 7% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 49). The nearest support is the swing low (Sep 1) at $75.88, and the nearest resistance the Pivot at $76.60.
| RSI (14) | 49.09 | Middle of its range | Neutral |
| MACD | 2.43 | Below its signal line | Bearish |
| Stochastic | 14.5 | Near the bottom of its range | Oversold |
| ADX (14) | 32.5 | Trending up | |
| Williams %R | -89.9 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -96.1 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −5.7% | Change over 10 sessions | Bearish |
| ATR (14) | $3.98 | Typical daily range, 5.2% of price |
| RSI (14) | 54.19 | Middle of its range | Neutral |
| MACD | 1.11 | Above its signal line | Bullish |
| Stochastic | 74.3 | Middle of its range | Neutral |
| ADX (14) | 19.0 | No clear trend | |
| Williams %R | -33.6 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 38.4 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +9.3% | Change over 10 sessions | Bullish |
| ATR (14) | $7.93 | Typical daily range, 10.4% of price |
What happened before
See how IRON did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How IRON has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in IRON in the last 90 days.
Dark Pool
30DIRON Institutional Ownership
Full report →- ▲135 buying vs 83 selling
- ▲Held by funds +1.0 pts
- ▲Funds holding +19
- ▼Superinvestors: 0 added, 2 cut
- ▼Put/call 0.18 to 1.17
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 237 | 218 | +8.7% |
| In funds' top 10 | 7 | 7 | 0.0% |
| Held by funds | 95.8% | 94.8% | +1.0 pts |
| New / increased | 43 / 92 | 36 / 75 | +21.6% |
| Reduced / sold out | 59 / 24 | 62 / 22 | −1.2% |
| Put/call ratio | 1.17 | 0.18 | +551.6% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IRON is in one of them and how their past IRON trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IRON in an article yet. Here's the latest on the wider market.
About Disc Medicine
Disc Medicine is a drug developer based in Watertown, Massachusetts, that focuses on treatments for serious blood disorders. Its work centers on the heme and iron pathways that help form red blood cells and carry oxygen. The company is developing bitopertin for porphyrias, DISC-0974 for anemia linked to myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease. Its product candidates are still in clinical development and are aimed at patients with blood diseases.
- Headquarters
- Watertown, MA

